Who Supplies Bisacodyl to India from JAPAN

To import finished pharmaceutical formulations containing Bisacodyl into India, the importing company must obtain an Import Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This process involves registering both the manufacturing site and the specific product. The application is submitted to the Drugs Controller General (I) at CDSCO, accompanied by necessary documents such as the manufacturing license, Good Manufacturing Practice (GMP) certificate, and Certificate of Pharmaceutical Product (COPP). The registration certificate is valid for three years and must be renewed nine months before expiration.

Additionally, an Import License is required for each consignment. This license is issued by CDSCO upon verification of the registration certificate and other compliance documents.

Imported pharmaceutical formulations containing Bisacodyl must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, is essential to demonstrate the product's shelf-life under India's climatic conditions. Upon arrival, customs drug inspectors perform port inspections to verify the authenticity and quality of the imported goods.

Between 2024 and 2026, the Indian government has implemented the Production Linked Incentive (PLI) scheme to encourage domestic manufacturing of pharmaceutical products, including formulations containing Bisacodyl. This initiative aims to reduce import dependency and boost local production. However, no significant bilateral agreements with Japan have been established during this period to facilitate pharmaceutical imports.

India imports finished Bisacodyl formulations primarily due to the demand for branded products, specific dosage forms, and formulations not produced domestically. The market size for Bisacodyl formulations in India is substantial, with a total export market of $8.6 million across 240 exporters to 108 countries.

The Basic Customs Duty (BCD) for Bisacodyl formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is levied on the BCD, resulting in a total duty of 20%. The Integrated Goods and Services Tax (IGST) is applicable as per the prevailing GST rates.

India sources Bisacodyl formulations from Japan due to the high quality, advanced manufacturing technologies, and adherence to international standards. Japanese manufacturers offer specialized dosage forms and formulations that may not be available domestically. While other countries like China, Germany, and the United States also supply Bisacodyl formulations, Japan's reputation for quality and innovation provides a competitive advantage.

India imports Bisacodyl formulations from Japan due to the availability of patented or branded products, specialized dosage forms, and formulations not produced domestically. Japanese manufacturers offer high-quality products that meet international standards, which are essential for the Indian market.

Compared to other sources like China, the European Union, and the United States, Japan offers superior quality, advanced manufacturing technologies, and adherence to international standards. While other countries may provide lower-priced alternatives, Japan's reputation for quality and reliability makes it a preferred choice for importing Bisacodyl formulations.

Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, it is advisable to diversify suppliers, maintain adequate inventory levels, and establish strong relationships with reliable partners.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stock to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letter of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order sizes with demand forecasts to optimize inventory.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure compliance with quality and regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the manufacturing site and product with CDSCO.
3. 3Drug Import License: Apply for an import license from CDSCO.
4. 4No Objection Certificate (NOC): If applicable, obtain an NOC from the Drug Controller Office.
5. 5Customs Broker: Engage a licensed customs house agent for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049099 to confirm classification and duty rates.

1. 1Certificate of Analysis (CoA): Confirming compliance with Indian Pharmacopoeia standards.
2. 2Certificate of Pharmaceutical Product (COPP): Issued by the regulatory authority in Japan.
3. 3Good Manufacturing Practice (GMP) Certificate: Demonstrating adherence to international manufacturing standards.
4. 4Drug Master File (DMF): Providing detailed information about the manufacturing process.
5. 5Stability Data: For ICH Zone IV conditions, demonstrating product shelf-life.
6. 6Free Sale Certificate: Indicating that the product is freely sold in Japan.
7. 7Manufacturer Authorization: Authorizing the Indian importer to distribute the product.

Upon arrival, customs drug inspectors perform port inspections to verify the authenticity and quality of the imported goods. Mandatory batch testing is conducted, including sample collection and analysis. Timelines for testing vary, and if a batch fails, it may be rejected or destroyed. Common quality issues from Japanese imports include discrepancies in labeling and packaging.